Tiziana Life Sciences Ltd(TLSA)Earnings, Financials & Key Ratios
TLSA•NASDAQ
$1.47
$187M mkt cap·Price updated May 6, 2026
AboutTiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.Show more
- Revenue$0
- EBITDA-$16M+12.4%
- Net Income-$12M+32.9%
- EPS (Diluted)-0.22+35.3%
- ROE-250.49%-77.7%
- ROIC-481.72%-14.5%
- Debt/Equity0.03-39.6%
- Interest Coverage-2632.33-46.4%
TLSA Key Insights
Tiziana Life Sciences Ltd (TLSA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 19.9x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TLSA Price & Volume
Tiziana Life Sciences Ltd (TLSA) stock price & volume — 10-year historical chart
Loading chart...
TLSA Growth Metrics
Tiziana Life Sciences Ltd (TLSA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-56.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-70.78%
Return on Capital
10 Years-431.28%
5 Years-133.31%
3 Years-172.91%
Last Year-329.69%
TLSA Recent Earnings
Tiziana Life Sciences Ltd (TLSA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 0/12 qtrs (0%)
Q3 2025Latest
Jul 8, 2025EPS
$0.10
Est $0.07
-35.4%
Revenue
—
Q3 2025
Jun 23, 2025EPS
$0.13
Revenue
—
Q2 2025
May 20, 2025EPS
$0.06
Revenue
—
Q3 2024
Jun 30, 2024EPS
$0.18
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2025Latest | Jul 8, 2025 | $0.10vs $0.07-35.4% | — |
| Q3 2025 | Jun 23, 2025 | $0.13 | — |
| Q2 2025 | May 20, 2025 | $0.06 | — |
| Q3 2024 | Jun 30, 2024 | $0.18 | — |
Based on last 12 quarters of dataView full earnings history →
TLSA Peer Comparison
Tiziana Life Sciences Ltd (TLSA) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ARCT | 259.5M | 9.13 | -3.80 | -51.43% | -88.75% | -29.13% | 0.12 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 |
Compare TLSA vs Peers
Tiziana Life Sciences Ltd (TLSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TLSA Income Statement
Tiziana Life Sciences Ltd (TLSA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 7.29M | 8.25M | 7.82M | 7.77M | 28.03M | 27.37M | 14.59M | 17.98M | 15.79M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 13.21M | 855K | 0 | 0 | 0 |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 2.96M | 4.67M | 4.34M | 2.91M | 5.99M | 13.21M | 12.96M | 8.11M | 5.23M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 4.33M | 3.57M | 3.48M | 4.86M | 8.82M | 13.31M | 1.63M | 9.87M | 10.56M |
| Operating Income | -7.29M▲ 0% | -8.25M▼ 13.1% | -7.82M▲ 5.1% | -7.77M▲ 0.7% | -28.03M▼ 260.6% | -27.37M▲ 2.3% | -14.59M▲ 46.7% | -17.98M▼ 23.3% | -15.79M▲ 12.2% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 15.39% | -13.14% | 5.12% | 0.65% | -260.56% | 2.33% | 46.72% | -23.3% | 12.18% |
| EBITDA | -7.28M | -8.23M | -7.81M | -7.58M | -27.94M | -27.23M | -14.54M | -17.89M | -15.67M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 15.49% | -13.12% | 5.14% | 3.03% | -268.8% | 2.52% | 46.63% | -23.07% | 12.4% |
| D&A (Non-Cash Add-back) | 8K | 11K | 12.61K | 198K | 89.76K | 141K | 51K | 96K | 124K |
| EBIT | -7.29M | -8.25M | -7.82M | -7.77M | -27.98M | -26.48M | -15.39M | -17.23M | -16.74M |
| Net Interest Income | 0 | 0 | 0 | -72K | -312K | -176K | -7K | 1.14M | 808K |
| Interest Income | 0 | 0 | 0 | 1K | 8K | 0 | 0 | 1.15M | 814K |
| Interest Expense | 9K | 9K | 9.46K | 73K | 320K | 176K | 7K | 10K | 6K |
| Other Income/Expense | -9K | -9K | -8.67K | -73K | -312K | 717K | -811K | 742K | -952K |
| Pretax Income | -7.3M▲ 0% | -8.26M▼ 13.1% | -7.83M▲ 5.1% | -7.85M▼ 0.2% | -28.34M▼ 261.2% | -26.66M▲ 5.9% | -15.4M▲ 42.2% | -17.24M▼ 12.0% | -16.75M▲ 2.9% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | -89K | -1.49M | -1.53M | -540K | -2.21M | -3.24M | 0 | 449K | -4.88M |
| Effective Tax Rate % | 1.22% | 17.99% | 19.58% | 6.88% | 7.79% | 12.15% | 0% | -2.6% | 29.16% |
| Net Income | -7.21M▲ 0% | -6.77M▲ 6.1% | -6.3M▲ 7.0% | -7.31M▼ 16.0% | -26.13M▼ 257.7% | -23.42M▲ 10.4% | -15.4M▲ 34.2% | -17.69M▼ 14.9% | -11.86M▲ 32.9% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 16.5% | 6.08% | 6.96% | -15.98% | -257.66% | 10.39% | 34.25% | -14.9% | 32.94% |
| Net Income (Continuing) | -7.21M | -6.77M | -6.3M | -7.31M | -26.13M | -23.42M | -15.4M | -17.69M | -11.86M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.14▲ 0% | -0.12▲ 14.3% | -0.09▲ 23.0% | -0.11▼ 19.0% | -0.54▼ 390.9% | -0.48▲ 11.1% | -0.30▲ 37.5% | -0.34▼ 13.3% | -0.22▲ 35.3% |
| EPS Growth % | 22.22% | 14.29% | 23% | -19.05% | -390.91% | 11.11% | 37.5% | -13.33% | 35.29% |
| EPS (Basic) | -0.14 | -0.12 | -0.09 | -0.11 | -0.54 | -0.48 | -0.30 | -0.34 | -0.22 |
| Diluted Shares Outstanding | 53.2M | 58.49M | 68.24M | 68.24M | 48.65M | 48.97M | 50.76M | 50.76M | 53.34M |
| Basic Shares Outstanding | 53.2M | 58.49M | 68.24M | 68.24M | 48.65M | 48.97M | 50.76M | 50.76M | 53.34M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
TLSA Balance Sheet
Tiziana Life Sciences Ltd (TLSA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.02M | 1.81M | 5.45M | 1.14M | 70.18M | 48.68M | 24.28M | 7.34M | 7.51M |
| Cash & Short-Term Investments | 4.7M | 48K | 4.18M | 153K | 65.82M | 42.19M | 18.12M | 1.18M | 3.72M |
| Cash Only | 4.7M | 48K | 4.18M | 153K | 65.82M | 42.19M | 18.12M | 1.18M | 3.72M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 3.78M | 5.27M | 5.86M | 6.05M | 3.69M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | -2.28K | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 320K | 1.76M | 1.27M | 991K | 193K | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 28K | 18K | 5.52K | 664K | 480K | 147K | 2.19M | 4.85M | 3.78M |
| Property, Plant & Equipment | 28K | 18K | 5.52K | 334K | 359.51K | 17K | 389K | 293K | 187K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | -35.59K | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 132.59K | 130K | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1.81M | 4.55M | 3.59M |
| Other Non-Current Assets | 0 | 0 | 0 | 330K | 23.49K | 0 | 0 | 0 | 0 |
| Total Assets | 5.05M▲ 0% | 1.83M▼ 63.7% | 5.45M▲ 197.8% | 1.81M▼ 66.8% | 70.66M▲ 3808.0% | 48.83M▼ 30.9% | 26.48M▼ 45.8% | 12.18M▼ 54.0% | 11.28M▼ 7.4% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | -45.39% | -63.75% | 197.84% | -66.85% | 3807.96% | -30.9% | -45.77% | -53.98% | -7.39% |
| Total Current Liabilities | 1.74M | 3.51M | 5.04M | 5.58M | 7.98M | 7.55M | 6.66M | 6.54M | 7.35M |
| Accounts Payable | 0 | 0 | 0 | 0 | 3.37M | 4.41M | 4.96M | 4.14M | 5.58M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 225K | 234K | 244.3K | 212K | 2.31M | 1.35M | 122K | 138K | 106K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 299K | 505K | 1.93M | 5.37M | 590.59K | -1.34M | -113K | -124K | -94K |
| Current Ratio | 2.89x | 0.52x | 1.08x | 0.21x | 8.79x | 6.45x | 3.64x | 1.12x | 1.02x |
| Quick Ratio | 2.89x | 0.52x | 1.08x | 0.21x | 8.79x | 6.45x | 3.64x | 1.12x | 1.02x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.44M | 3.01M | 3.11M | 411K | 290K | 0 | 243K | 109K | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 289.79K | 0 | 243K | 109K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.44M | 3.01M | 3.11M | 411K | 207 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.74M | 3.51M | 5.04M | 5.99M | 8.27M | 7.55M | 6.91M | 6.65M | 7.35M |
| Total Debt | 225K | 234K | 244.3K | 623K | 555K | 1.35M | 365K | 247K | 106K |
| Net Debt | -4.48M | 186K | -3.94M | 470K | -65.27M | -42.19M | -17.76M | -936K | -3.62M |
| Debt / Equity | 0.07x | - | 0.60x | - | 0.01x | 0.03x | 0.02x | 0.04x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -809.78x | -916.22x | -827.33x | -106.48x | -87.58x | -155.53x | -2083.71x | -1798.40x | -2632.33x |
| Total Equity | 3.31M▲ 0% | -1.68M▼ 150.8% | 409.01K▲ 124.3% | -4.18M▼ 1122.0% | 62.39M▲ 1592.5% | 41.28M▼ 33.8% | 19.57M▼ 52.6% | 5.54M▼ 71.7% | 3.94M▼ 28.9% |
| Equity Growth % | -61.03% | -150.78% | 124.3% | -1121.97% | 1592.49% | -33.83% | -52.59% | -71.71% | -28.9% |
| Book Value per Share | 0.06 | -0.03 | 0.01 | -0.06 | 1.28 | 0.84 | 0.39 | 0.11 | 0.07 |
| Total Shareholders' Equity | 3.31M | -1.68M | 409.01K | -4.18M | 45.71M | 41.28M | 19.57M | 5.54M | 3.94M |
| Common Stock | 2.83M | 3.75M | 6.77M | 4.1M | 97K | 102K | 102K | 103K | 111K |
| Retained Earnings | 11.04M | -29.75M | -39.9M | -43.15M | -84.65M | -108.06M | -116.26M | -133.68M | -144.83M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -1.32M | -1.57M | 0 |
| Accumulated OCI | -8K | -19K | -30.73K | -35K | -52K | 119.15M | 115.57M | 117.06M | 116.99M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TLSA Cash Flow Statement
Tiziana Life Sciences Ltd (TLSA) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.62M | -5.68M | -3.63M | -5.29M | -8.76M | -16.13M | -15.99M | -12.42M | -1.22M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 1.43% | -1.16% | 36.1% | -45.78% | -65.48% | -84.22% | 0.88% | 22.31% | 90.18% |
| Net Income | -7.92M | -6.57M | -6.26M | -7.26M | -19.17M | -17.36M | -12.55M | -14M | -9.48M |
| Depreciation & Amortization | 8.79K | 10.68K | 12.62K | 194.77K | 65.93K | 104.52K | 41.57K | 75.97K | 99.09K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.35M | -895.98K | 1.08M | 1.55M | 10.56M | 1.7M | -2.53M | 2.75M | 8.6M |
| Working Capital Changes | 951.66K | 1.78M | 1.53M | 223.59K | -215.69K | -573.01K | -948.89K | -1.25M | -441.1K |
| Change in Receivables | 0 | 38.83K | -142K | -99.37K | -342.85K | 317.27K | -127.17K | -1.14M | -1.11M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -276.93K | -970 | 0 | -2.98K | -93.25K | 96.36K | -3.26M | -991.57K | -56.73K |
| Capital Expenditures | -38.46K | -970 | 0 | -2.98K | -93.25K | -16.31K | 0 | 0 | -15.18K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 112.67K | -1.08M | -200.21K | 10.45K |
| Cash from Financing | 1.28M | 1.16M | 7.96M | 1.31M | 54.12M | -17.05K | -44.84K | 31.65K | 3.6M |
| Debt Issued (Net) | 779.13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -141K |
| Equity Issued (Net) | 497.81K | 1000K | 1000K | 1000K | 1000K | 95.63K | 0 | 125.83K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | -156.02K | -203.45K | -112.67K | -44.84K | -94.17K | 28.33K |
| Net Change in Cash | -5.95M▲ 0% | -4.33M▲ 27.3% | 4.13M▲ 195.4% | -3.97M▼ 196.2% | 48.26M▲ 1314.4% | -17.59M▼ 136.4% | -19.62M▼ 11.5% | -13.4M▲ 31.7% | 2.03M▲ 115.1% |
| Free Cash Flow | -5.65M▲ 0% | -5.68M▼ 0.5% | -3.63M▲ 36.1% | -5.29M▼ 45.9% | -8.76M▼ 65.4% | -16.15M▼ 84.4% | -15.99M▲ 1.0% | -12.42M▲ 22.3% | -1.23M▲ 90.1% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 0.75% | -0.49% | 36.11% | -45.86% | -65.43% | -84.36% | 0.98% | 22.31% | 90.06% |
| FCF per Share | -0.11 | -0.10 | -0.05 | -0.08 | -0.18 | -0.33 | -0.31 | -0.24 | -0.02 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.84x | 0.58x | 0.72x | 0.34x | 0.69x | 1.04x | 0.70x | 0.10x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TLSA Key Ratios
Tiziana Life Sciences Ltd (TLSA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -167.92% | -121.98% | -830.17% | -1540.08% | - | -89.79% | -45.18% | -50.61% | -140.92% | -250.49% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | -4572.49% | -966.81% | -420.58% | -481.72% |
| Debt / Equity | 0.03x | 0.07x | - | 0.60x | - | 0.01x | 0.03x | 0.02x | 0.04x | 0.03x |
| Interest Coverage | -478.56x | -809.78x | -916.22x | -827.33x | -106.48x | -87.58x | -155.53x | -2083.71x | -1798.40x | -2632.33x |
| FCF Conversion | 0.66x | 0.78x | 0.84x | 0.58x | 0.72x | 0.34x | 0.69x | 1.04x | 0.70x | 0.10x |
TLSA Frequently Asked Questions
Tiziana Life Sciences Ltd (TLSA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tiziana Life Sciences Ltd (TLSA) grew revenue by 0.0% over the past year. Growth has been modest.
Tiziana Life Sciences Ltd (TLSA) reported a net loss of $34.2M for fiscal year 2024.
Dividend & Returns
Tiziana Life Sciences Ltd (TLSA) has a return on equity (ROE) of -250.5%. Negative ROE indicates the company is unprofitable.
Tiziana Life Sciences Ltd (TLSA) had negative free cash flow of $13.6M in fiscal year 2024, likely due to heavy capital investments.
Explore More TLSA
Tiziana Life Sciences Ltd (TLSA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates